In The Lancet, Robert Croop and colleagues present a carefully designed phase 3 trial on an oral disintegrating tablet (ODT) of rimegepant for the acute treatment of migraine among 1375 patients (85% female, mean age 40·2 years [SD 12·0]). The trial was positive, showing an increase in relief from headache pain among the group receiving rimegepant at 2 h after dosing (10% over placebo) and improvement in the most bothersome symptoms, which included photophobia and nausea (8% over placebo). The onset was reported to be slightly faster than that of other gepants (first positive effect at 1 h for rimegepant vs 2 h for telcagepant) and the effect on the lower side (10% for rimegepant vs a mean of 17% in four trials on telcagepant), but the duration was up to 48 h. Adverse events were not different from placebo.

中文翻译：

---

Rimegepant偏头痛口服崩解片

在《柳叶刀》杂志上，Robert Croop及其同事介绍了一种精心设计的瑞格非特口服崩解片（ODT）的3期试验，用于1375例患者的偏头痛的急性治疗（女性占85％，平均年龄40·2岁[SD 12·0] ]）。该试验是阳性的，显示在给药后2小时接受瑞格明的组中头痛疼痛的缓解有所增加（比安慰剂高10％），并且最令人不适的症状有所改善，其中包括畏光和恶心（比安慰剂高8％）。发病报道比其他gepants（在用于rimegepant 1个小时第一正效果的更快稍微VS为替卡格泮2 h）和下侧（效果10％rimegepant VS在四次telcagepant试验中平均为17％），但持续时间长达48小时。不良事件与安慰剂无异。